Metastatic breast cancer
Adult: As albumin bound paclitaxel nanoparticles: 260 mg/m2 over 30 minutes every 3 weeks. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).
Intravenous
Breast cancer
Adult: As 6 mg/mL conventional solution: Adjuvant therapy in patient with node-positive cases following anthracycline-containing regimen: 175 mg/m2 infused over 3 hours once every 3 weeks for 4 cycles. 1st line treatment in combination with doxorubicin: 220 mg/m2 via infusion over 3 hours once every 3 weeks. 2nd line treatment as monotherapy: 175 mg/m2 via infusion over 3 hours once every 3 weeks. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).
Intravenous
HER2-overexpressing advanced or metastatic breast cancer
Adult: As 6 mg/mL conventional solution in combination with trastuzumab: 175 mg/m2 infused over 3 hours once every 3 weeks. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).
Intravenous
Advanced ovarian carcinoma
Adult: As conventional 6 mg/mL solution: Primary treatment in combination with cisplatin: 175 mg/m2 infused over 3 hours every 3 weeks. Alternatively, 135 mg/m2 infused over 24 hours, repeated at 3-week intervals. Secondary treatment as monotherapy: 175 mg/m2 infused over 3 hours once every 3 weeks. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).
Intravenous
Locally advanced non-small cell lung carcinoma, Metastatic non-small cell lung carcinoma
Adult: As albumin bound paclitaxel nanoparticles in combination with carboplatin: 100 mg/m2 infused over 30 minutes, on days 1, 8, and 15 of a 21-day cycle. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).
Intravenous
Advanced non-small cell lung cancer
Adult: As 6 mg/mL conventional solution in combination with cisplatin: 175 mg/m2 infused over 3 hours or 135 mg/m2 over 24 hours, repeated at 3-week intervals. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).
Intravenous
Metastatic adenocarcinoma of pancreas
Adult: As albumin bound paclitaxel nanoparticles in combination of gemcitabine: 125 mg/m2 over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).
Intravenous
AIDS-related Kaposi's sarcoma
Adult: As 6 mg/mL conventional solution: 100 mg/m2 infused over 3 hours every 2 weeks. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).